Pharmacokinetic Study of Carboplatin in Pediatric Hematopoietic Stem Cell Transplantation
Status:
Unknown status
Trial end date:
2016-12-01
Target enrollment:
Participant gender:
Summary
Carboplatin is widely used for conditioning regimens of autologous hematopoietic stem cell
transplantation for pediatric solid tumor, but the pharmacokinetics has not been evaluated in
pediatric stem cell transplantation before. As carboplatin have renal toxicity, the
pharmacokinetic study of carboplatin would help the safe and effective administration of
carboplatin for transplantation patients. Especially, the dose of carboplatin is higher at
conditioning chemotherapy, resulting in higher toxicity.
Carboplatin is a drug mostly excreted by kidney, and the dose of carboplatin is recommended
according to the body surface area and kidney function, represented by glomerular filtration
rate. After analyzing the pharmacokinetics of carboplatin, analyses will also be done for the
methods to determine the appropriate carboplatin dose.
Phase:
Phase 2
Details
Lead Sponsor:
The Korean Society of Pediatric Hematology Oncology